Department of Nephrology and Blood Purification, Kidney Disease Center, Tokyo Medical University Hachioji Medical Center, Hachioji 193-0998, Japan.
Int J Mol Sci. 2024 May 29;25(11):5931. doi: 10.3390/ijms25115931.
Following the discovery of podocyte phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A, various potential target antigens for membranous nephropathy (MN) have been reported one after another. MN target antigens have now been identified in a significant proportion of patients, and a new classification framework classifies patients with MN based on the detected antigen and associated disease phenotype. A serology-based approach that does not require a histological diagnosis for patients suspected of having MN has also been proposed. However, there have been cases in which dual positivity for MN antigens and/or corresponding antibodies has been shown. Importantly, some of them showed a transition of the affected patient's immune responses to MN antigens, suggesting that serological diagnosis changes depending on the timing of the analysis. In this review, we provide detailed information on these cases and present an overview of our recent understanding of their putative mechanisms involved in these cases. Greater awareness is required to adequately recognize and develop appropriate therapeutic strategies for this condition.
继足细胞磷脂酶 A2 受体和血栓反应蛋白-1 型结构域包含蛋白 7A 被发现后,陆续有报道称各种潜在的膜性肾病 (MN) 靶抗原。目前,MN 靶抗原已在相当一部分患者中得到确认,一种新的分类框架根据检测到的抗原和相关疾病表型对 MN 患者进行分类。还提出了一种基于血清学的方法,无需对疑似 MN 患者进行组织学诊断。然而,有一些病例显示 MN 抗原和/或相应抗体的双重阳性。重要的是,其中一些患者的免疫反应对 MN 抗原的影响发生了转变,这表明血清学诊断会随着分析时间的变化而改变。在这篇综述中,我们详细介绍了这些病例,并概述了我们对这些病例中潜在机制的最新理解。为了充分认识和制定针对这种疾病的适当治疗策略,需要提高认识。